Open Access

Characterization of triple negative breast cancer gene expression profiles in Mexican patients

  • Authors:
    • Eric Ortiz Valdez
    • Claudia Rangel‑Escareño
    • Juan Antonio Matus Santos
    • Rafael Vázquez Romo
    • Alberto Guijosa
    • Cynthia Villarreal‑Garza
    • Oscar Arrieta
    • Rubén Rodríguez‑Bautista
    • Claudia H. Caro‑Sánchez
    • Alette Ortega Gómez
  • View Affiliations

  • Published online on: December 15, 2022     https://doi.org/10.3892/mco.2022.2601
  • Article Number: 5
  • Copyright: © Ortiz Valdez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Triple negative breast cancer (TNBC) is an aggressive type of cancer that accounts for ~23% of breast tumors in Mexico. In an attempt to understand in an improved way the behavior of TNBC, throughout the years, gene expression in these tumors has been studied. Lehman et al identified 6 subtypes of gene expression in TNBC with distinct characteristics. In the present study, it was aimed to assess clinical, pathological and prognostic characteristics of TNBC in a Mexican‑based cohort. A total of 55 patients diagnosed with TNBC at Mexico's National Institute of Cancer (INCan) were included. Tumor needle biopsy samples were obtained and subjected to microarray analysis. Patients were thus classified into one of the 6 TNBC molecular subtypes. The prognostic, clinical and pathological information of patients was obtained, and differences across molecular subtypes were sought. Out of the 55 included patients, the following subtypes were identified: 9 basal‑like‑1, 11 basal‑like‑2 (BSL2), 16 immunomodulatory (IM), 12 mesenchymal, 6 androgen receptor‑like and 1 mesenchymal stem‑like. Mean follow‑up time was 47.1 months. The IM molecular subtype had the best overall survival (OS) (median OS was not reached). BSL2 had the worst OS (15 months). A complete pathologic response to neoadjuvant chemotherapy was obtained more often in the IM subtype (P=0.032). No significant associations were found between any of the clinical or pathological characteristics and the TNBC molecular subtypes. The results obtained from the present study should be considered when seeking to implement a clinical‑molecular model for TNBC patient care, particularly in Hispanic‑based populations, as they have been frequently underrepresented in clinical studies assessing TNBC molecular subtypes.
View Figures
View References

Related Articles

Journal Cover

January-2023
Volume 18 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ortiz Valdez E, Rangel‑Escareño C, Matus Santos J, Vázquez Romo R, Guijosa A, Villarreal‑Garza C, Arrieta O, Rodríguez‑Bautista R, Caro‑Sánchez CH, Ortega Gómez A, Ortega Gómez A, et al: Characterization of triple negative breast cancer gene expression profiles in Mexican patients. Mol Clin Oncol 18: 5, 2023.
APA
Ortiz Valdez, E., Rangel‑Escareño, C., Matus Santos, J., Vázquez Romo, R., Guijosa, A., Villarreal‑Garza, C. ... Ortega Gómez, A. (2023). Characterization of triple negative breast cancer gene expression profiles in Mexican patients. Molecular and Clinical Oncology, 18, 5. https://doi.org/10.3892/mco.2022.2601
MLA
Ortiz Valdez, E., Rangel‑Escareño, C., Matus Santos, J., Vázquez Romo, R., Guijosa, A., Villarreal‑Garza, C., Arrieta, O., Rodríguez‑Bautista, R., Caro‑Sánchez, C. H., Ortega Gómez, A."Characterization of triple negative breast cancer gene expression profiles in Mexican patients". Molecular and Clinical Oncology 18.1 (2023): 5.
Chicago
Ortiz Valdez, E., Rangel‑Escareño, C., Matus Santos, J., Vázquez Romo, R., Guijosa, A., Villarreal‑Garza, C., Arrieta, O., Rodríguez‑Bautista, R., Caro‑Sánchez, C. H., Ortega Gómez, A."Characterization of triple negative breast cancer gene expression profiles in Mexican patients". Molecular and Clinical Oncology 18, no. 1 (2023): 5. https://doi.org/10.3892/mco.2022.2601